Published Online
on November 4, 2002

A more recent version of this article appeared on November 26, 2002

This Article Full Text (PDF) All Versions of this Article: 106/22/2812    most recent 01.CIR.0000038946.91899.BBv1 Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Longenecker, J. C. Articles by Coresh, J. Search for Related Content PubMed PubMed Citation Articles by Longenecker, J. C. Articles by Coresh, J. Pubmed/NCBI databases Substance via MeSH Related Collections Lipids Epidemiology

Submitted on June 21, 2002
Revised on September 10, 2002
Accepted on September 10, 2002

Small Apolipoprotein(a) Size Predicts Mortality in End-Stage Renal Disease. The CHOICE Study

J. Craig Longenecker MD, PhD^*, Michael J. Klag MD, MPH, Santica M. Marcovina PhD, DSc, Neil R. Powe MD, MPH, Nancy E. Fink MPH, Federico Giaculli MD, and Josef Coresh MD, PhD

From Johns Hopkins University, Baltimore, Md, and Northwest Lipid Research Laboratories, University of Washington (S.M.M., F.G.), Seattle, Wash. Dr Giaculli is now at the University of Padua, Italy.

^* To whom correspondence should be addressed. E-mail: jlongene{at}jhsph.edu.

Background—The high mortality rate in end-stage renal disease has engendered interest in nontraditional atherosclerotic cardiovascular disease (ASCVD) risk factors that are more prevalent in end-stage renal disease, such as elevated lipoprotein(a) [Lp(a)] levels. Previous studies suggest that high Lp(a) levels and small apolipoprotein(a) [apo(a)] isoform size are associated with ASCVD, but none have investigated the relationship between Lp(a) level, apo(a) size, and mortality.

Methods and Results—An inception cohort of 864 incident dialysis patients was followed prospectively. Lp(a) was measured by an apo(a) size-independent ELISA and apo(a) size by Western blot after SDS-agarose gel electrophoresis. Comorbid conditions were determined by medical record review. Time to death was ascertained through dialysis clinic and Health Care Financing Administration follow-up. Survival analyses were performed with adjustment for baseline demographic, comorbid conditions, albumin, and lipids. Median follow-up was 33.7 months, with 346 deaths, 162 transplantations, and 10 losses to follow-up during 1999 person-years of follow-up. Cox regression analysis showed no association between Lp(a) level and mortality. However, an association between small apo(a) isoform size and mortality was found (hazard ratio, 1.36; P=0.004) after adjusting for age, race, sex, comorbidity score, cause of renal disease, and congestive heart failure. The association was somewhat lower in white patients (hazard ratio 1.34; P=0.019) than in black patients (1.69; P=0.04). No interaction by age, race, sex, diabetes, ASCVD, or Lp(a) level was present.

Conclusions—Small apo(a) size, but not Lp(a) level, independently predicts total mortality risk in dialysis patients.

Key words: lipoproteins • mortality • kidney

This article has been cited by other articles:

				B. Dieplinger, A. Lingenhel, N. Baumgartner, W. Poelz, H. Dieplinger, M. Haltmayer, F. Kronenberg, and T. Mueller Increased Serum Lipoprotein(a) Concentrations and Low Molecular Weight Phenotypes of Apolipoprotein(a) Are Associated with Symptomatic Peripheral Arterial Disease Clin. Chem., July 1, 2007; 53(7): 1298 - 1305. [Abstract] [Full Text] [PDF]

				J. Rubin, H. J. Kim, T. A. Pearson, S. Holleran, R. Ramakrishnan, and L. Berglund Apo[a] size and PNR explain African American-Caucasian differences in allele-specific apo[a] levels for small but not large apo[a] J. Lipid Res., May 1, 2006; 47(5): 982 - 989. [Abstract] [Full Text] [PDF]

				L. E. Boulware, Y. Liu, N. E. Fink, J. Coresh, D. E. Ford, M. J. Klag, and N. R. Powe Temporal Relation among Depression Symptoms, Cardiovascular Disease Events, and Mortality in End-Stage Renal Disease: Contribution of Reverse Causality Clin. J. Am. Soc. Nephrol., May 1, 2006; 1(3): 496 - 504. [Abstract] [Full Text] [PDF]

				R. S. Parekh, L. Zhang, B. A. Fivush, and M. J. Klag Incidence of Atherosclerosis by Race in the Dialysis Morbidity and Mortality Study: A Sample of the US ESRD Population J. Am. Soc. Nephrol., May 1, 2005; 16(5): 1420 - 1426. [Abstract] [Full Text] [PDF]

				L. Berglund and R. Ramakrishnan Lipoprotein(a): An Elusive Cardiovascular Risk Factor Arterioscler Thromb Vasc Biol, December 1, 2004; 24(12): 2219 - 2226. [Abstract] [Full Text] [PDF]

				C. H. Saely, T. Marte, H. Drexel, C. P. Kovesdy, A. A. Ariyo, R. P. Tracy, and C. Thach Lp(a) Lipoprotein, Vascular Disease, and Mortality in the Elderly N. Engl. J. Med., March 11, 2004; 350(11): 1150 - 1152. [Full Text] [PDF]

				P. Muntner, L. L. Hamm, J. W. Kusek, J. Chen, P. K. Whelton, and J. He The Prevalence of Nontraditional Risk Factors for Coronary Heart Disease in Patients with Chronic Kidney Disease Ann Intern Med, January 6, 2004; 140(1): 9 - 17. [Abstract] [Full Text] [PDF]

				M. J. Sarnak, A. S. Levey, A. C. Schoolwerth, J. Coresh, B. Culleton, L. L. Hamm, P. A. McCullough, B. L. Kasiske, E. Kelepouris, M. J. Klag, et al. Kidney Disease as a Risk Factor for Development of Cardiovascular Disease: A Statement From the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention Hypertension, November 1, 2003; 42(5): 1050 - 1065. [Full Text] [PDF]

				M. J. Sarnak, A. S. Levey, A. C. Schoolwerth, J. Coresh, B. Culleton, L. L. Hamm, P. A. McCullough, B. L. Kasiske, E. Kelepouris, M. J. Klag, et al. Kidney Disease as a Risk Factor for Development of Cardiovascular Disease: A Statement From the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention Circulation, October 28, 2003; 108(17): 2154 - 2169. [Full Text] [PDF]